citybiz.co

Vertex Completes $10B Crinetics Acquisition and Expands Executive Team

Vertex Pharmaceuticals logoVertex Pharmaceuticals
Sig5.82Sen+6.45Env0.00Soc+1.25Gov+1.15
Crinetics Pharmaceuticals logoCrinetics Pharmaceuticals
Sig4.20Sen+6.60Env0.00Soc+1.20Gov+1.10

Vertex Pharmaceuticals completed its approximately $10 billion acquisition of Crinetics Pharmaceuticals, adding a commercial endocrine therapy and late-stage clinical programs. The company is restructuring its executive leadership to oversee integration across product launches, clinical development, regulatory operations and the Crinetics workforce. Charles Wagner expands COO duties to lead integration, and Jasper van Grunsven joins Sept. 8 to lead the pain franchise and global new product planning.

Coverage (1)

ABOUT

What is Fimmer?

Most feeds treat all company headlines the same. An executive interview, an office closure, stock analysis, and a data breach can sit side by side with no sense of scale. Fimmer ranks coverage by what matters, so important events stand out and signals are prioritised over noise. We cluster related company news and score each story using a range of metrics, so you see the most crucial stories first.

SCORING

What do the scores mean?

Significance (0–10) measures the scale of the real-world impact. Sentiment and ESG (−10 to +10) indicate the tone of the coverage and whether the change relates to environmental, social, or governance factors. Together, these scores help distinguish meaningful developments from routine company news. More information about our scoring methodology can be found on our About page.

DISCOVERY

Explore more on Fimmer

Search more than 10,000 public companies, browse the company index, explore their scores, and read the coverage behind them, with our core features available to everyone for free.

For more advanced features, Pro gives you access to dynamic feeds, custom sorting, and more ways to track the companies that matter to you.

More with Pro